6 November 2020 in Cancer Science
Neoantigens have attracted attention as biomarkers or therapeutic targets. However, accurate prediction of neoantigens is still challenging, especially in terms of its accuracy and cost. Variant detection using RNA sequencing (RNA‐seq) data has been reported to be a low‐accuracy but cost‐effective tool, but the feasibility of RNA‐seq data for neoantigen prediction has not been fully examined. In the present study, we used whole‐exome sequencing (WES) and RNA‐seq data of tumor and matched normal samples from six breast cancer patients to evaluate the utility of RNA‐seq data instead of WES data in variant calling to detect neoantigen candidates. Somatic variants were called in three protocols using: (i) tumor and normal WES data (DNA method, Dm); (ii) tumor and normal RNA‐seq data (RNA method, Rm); and (iii) combination of tumor RNA‐seq and normal WES data (Combination method, Cm). We found that the Rm had both high false‐positive and high false‐negative rates because this method depended greatly on the expression status of normal transcripts. When we compared the results of Dm with those of Cm, only 14% of the neoantigen candidates detected in Dm were identified in Cm, but the majority of the missed candidates lacked coverage or variant allele reads in the tumor RNA. In contrast, about 70% of the neoepitope candidates with higher expression and rich mutant transcripts could be detected in Cm. Our results showed that Cm could be an efficient and a cost‐effective approach to predict highly expressed neoantigens in tumor samples.
2 September 2025 in Proceedings of the National Academy of Sciences
Metastasis remains the leading cause of cancer-related mortality, driven by complex interactions within the tumor microenvironment (TME). Tumor-associated macrophages (TAMs) play a pivotal role in metastatic progression, yet their molecular diversity and upstream regulators remain poorly defined. Glycoprotein nonmetastatic melanoma protein B (GPNMB), overexpressed in subsets of tumors including triple-negative breast cancer (TNBC), is implicated in epithelial–mesenchymal transition (EMT) and cancer stemness. Recent single-cell RNA sequencing (scRNA-seq) identified GPNMB as a marker of immunosuppressive TAMs associated with poor prognosis, but its mechanistic role in TNBC has remained unclear. Coculturing monocytic cells with three-dimensional TNBC spheres induced GPNMB + TAMs expressing sialic acid-binding immunoglobulin-like lectin 9 (Siglec-9). Tumor-expressed GPNMB promotes monocyte-to-TAM polarization by inducing secondary GPNMB expression in monocytes, establishing a feed-forward amplification loop. GPNMB knockdown in TNBC cells inhibited immunosuppressive TAM subsets, including Siglec-9 + and EMT-associated populations, as determined by deconvolution of bulk RNA-seq data using a custom TAM signature matrix derived from publicly available TNBC scRNA-seq datasets. TNBC-derived GPNMB carried α2,3-sialylation, whereas macrophage-derived GPNMB carried α2,6-sialylation, enabling differential Siglec-9 recognition. Elevated GPNMB and Siglec-9 correlated with poor prognosis in TNBCcohorts. Importantly, dual inhibition of Siglec-E (murine Siglec-9 ortholog) and PD-1 reduced tumor stemness, suppressed IL-6-dependent EMT, and limited lung metastasis in vivo. The GPNMB–Siglec-9 axis thus represents a critical glyco-immunological checkpoint driving TAM-mediated metastasis, providing a promising therapeutic target in TNBC.
24 July 2026 in International Cancer Conference Journal
Radiation recall phenomenon (RRP) is an inflammatory reaction occurring in previously irradiated tissues after exposure to certain drugs, and very late-onset cases are exceptionally rare. We report a 58-year-old woman with Human Epidermal Growth Factor Receptor 2 (HER2)-positive, estrogen receptor (ER) / progesterone receptor (PgR)-positive invasive ductal carcinoma of the left breast who had undergone contralateral mastectomy and radiotherapy 32 years earlier. During neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab, she developed rapidly progressive ulceration and necrosis confined to the prior radiation field on the right chest wall. Docetaxel and carboplatin were discontinued while trastuzumab and pertuzumab were continued. Intensive dermatologic management, including repeated surgical debridement and topical therapy, was required, and substantial epithelialization was achieved only after an approximately two-year course, highlighting a protracted recovery. The clinical course was considered most consistent with severe late-onset radiation recall dermatitis (RRD) superimposed on chronically vulnerable irradiated tissue. Clinicians should consider RRD during systemic therapy in patients with a history of radiotherapy, even decades after treatment, and should distinguish it from chronic radiation injury, infection, and recurrent cancer.